| Adam Joseph Todd, | |
|
3601 Minnesota Dr Ste 200, Bloomington, MN 55435-5281 | |
| (612) 879-1000 | |
| (612) 879-9116 |
| Full Name | Adam Joseph Todd |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 18 Years |
| Location | 3601 Minnesota Dr Ste 200, Bloomington, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124210885 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 53495 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abbott Northwestern Hospital | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Noran Neurological Clinic, Pa | 3971497389 | 47 |
| Allina Health System | 4587573613 | 3071 |
News Archive
At their annual meeting the Royal College of Nursing heard arguments in favour of terminally-ill patients having the right to decide when and how to end their lives.
In a paper in this month's premier open-access medical journal PLoS Medicine, Mark Larche and colleagues from Imperial College London describe a subset of cells that might be able to suppress cells that cause cat allergy.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
Driven by the need for a tool to address African genomic diversity, Illumina was selected to develop an array for genome-wide association studies (GWAS) by the Human Heredity and Health in Africa (H3Africa) Initiative, a partnership between NIH, the African Society of Human Genetics, and Wellcome Trust.
› Verified 5 days ago
| Entity Name | Ridgeview Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528364429 PECOS PAC ID: 9234041997 Enrollment ID: O20031111000183 |
News Archive
At their annual meeting the Royal College of Nursing heard arguments in favour of terminally-ill patients having the right to decide when and how to end their lives.
In a paper in this month's premier open-access medical journal PLoS Medicine, Mark Larche and colleagues from Imperial College London describe a subset of cells that might be able to suppress cells that cause cat allergy.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
Driven by the need for a tool to address African genomic diversity, Illumina was selected to develop an array for genome-wide association studies (GWAS) by the Human Heredity and Health in Africa (H3Africa) Initiative, a partnership between NIH, the African Society of Human Genetics, and Wellcome Trust.
› Verified 5 days ago
| Entity Name | Noran Neurological Clinic, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710098306 PECOS PAC ID: 3971497389 Enrollment ID: O20040209000324 |
News Archive
At their annual meeting the Royal College of Nursing heard arguments in favour of terminally-ill patients having the right to decide when and how to end their lives.
In a paper in this month's premier open-access medical journal PLoS Medicine, Mark Larche and colleagues from Imperial College London describe a subset of cells that might be able to suppress cells that cause cat allergy.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
Driven by the need for a tool to address African genomic diversity, Illumina was selected to develop an array for genome-wide association studies (GWAS) by the Human Heredity and Health in Africa (H3Africa) Initiative, a partnership between NIH, the African Society of Human Genetics, and Wellcome Trust.
› Verified 5 days ago
| Entity Name | Minnesota Valley Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730248907 PECOS PAC ID: 9032006507 Enrollment ID: O20040301000309 |
News Archive
At their annual meeting the Royal College of Nursing heard arguments in favour of terminally-ill patients having the right to decide when and how to end their lives.
In a paper in this month's premier open-access medical journal PLoS Medicine, Mark Larche and colleagues from Imperial College London describe a subset of cells that might be able to suppress cells that cause cat allergy.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
Driven by the need for a tool to address African genomic diversity, Illumina was selected to develop an array for genome-wide association studies (GWAS) by the Human Heredity and Health in Africa (H3Africa) Initiative, a partnership between NIH, the African Society of Human Genetics, and Wellcome Trust.
› Verified 5 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
At their annual meeting the Royal College of Nursing heard arguments in favour of terminally-ill patients having the right to decide when and how to end their lives.
In a paper in this month's premier open-access medical journal PLoS Medicine, Mark Larche and colleagues from Imperial College London describe a subset of cells that might be able to suppress cells that cause cat allergy.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
Driven by the need for a tool to address African genomic diversity, Illumina was selected to develop an array for genome-wide association studies (GWAS) by the Human Heredity and Health in Africa (H3Africa) Initiative, a partnership between NIH, the African Society of Human Genetics, and Wellcome Trust.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adam Joseph Todd, 3601 Minnesota Dr Ste 200, Bloomington, MN 55435-5281 Ph: (612) 879-1000 | Adam Joseph Todd, 3601 Minnesota Dr Ste 200, Bloomington, MN 55435-5281 Ph: (612) 879-1000 |
News Archive
At their annual meeting the Royal College of Nursing heard arguments in favour of terminally-ill patients having the right to decide when and how to end their lives.
In a paper in this month's premier open-access medical journal PLoS Medicine, Mark Larche and colleagues from Imperial College London describe a subset of cells that might be able to suppress cells that cause cat allergy.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
Driven by the need for a tool to address African genomic diversity, Illumina was selected to develop an array for genome-wide association studies (GWAS) by the Human Heredity and Health in Africa (H3Africa) Initiative, a partnership between NIH, the African Society of Human Genetics, and Wellcome Trust.
› Verified 5 days ago
Sean Sullivan Dwyer, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3601 Minnesota Dr Ste 200, Bloomington, MN 55435 Phone: 612-879-1000 Fax: 612-879-9116 | |
Erika L. Wexler, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3601 Minnesota Dr Ste 200, Bloomington, MN 55435 Phone: 612-879-1000 Fax: 612-879-0722 | |
Syed Mustafa Shahkhan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3601 Minnesota Dr Ste 200, Bloomington, MN 55435 Phone: 612-879-1000 Fax: 612-879-9116 | |
Eleanor K Orehek, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3601 Minnesota Dr Ste 200, Bloomington, MN 55435 Phone: 612-879-1000 Fax: 612-879-9116 | |
John A Damergis Jr., M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3601 Minnesota Dr Ste 200, Bloomington, MN 55435 Phone: 612-879-1000 Fax: 612-879-9116 | |
Katherine Ferguson, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3601 Minnesota Dr Ste 200, Bloomington, MN 55435 Phone: 161-287-9100 Fax: 612-879-9116 |